The National Pharmaceutical Council President and CEO & Former Trump Drug Pricing Advisor, John O’Brien, PharmD, MPH episode artwork

EPISODE · Jan 8, 2026 · 37 MIN

The National Pharmaceutical Council President and CEO & Former Trump Drug Pricing Advisor, John O’Brien, PharmD, MPH

from Perspectives by the Leerink Center for Pharmacoeconomics · host The Leerink Center for Pharmacoeconomics

Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, talks with John M. O'Brien, PharmD, MPH, President and CEO of the National Pharmaceutical Council & Former Trump Drug Pricing Advisor, to tackle some big questions like if it is possible to reward innovation without busting budgets and how to get to a sustainable, innovation-friendly, patient-centered drug pricing system. Additional resources: Subscribe to NPC’s Newsletter https://www.npcnow.org/subscribe-updates IRA Impact on Pharmaceutical Investment: Insights From Investor Interviews (Health Affairs Scholar) https://academic.oup.com/healthaffairsscholar/article/3/9/qxaf156/8223954 How Time Is Accounted For When Modeling Pharmaceutical Impacts: Investment vs Assessment Perspectives (Health Affairs Scholar) https://academic.oup.com/healthaffairsscholar/article/3/9/qxaf169/8244606 The IRA and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials (Therapeutic Innovation & Regulatory Science) https://link.springer.com/article/10.1007/s43441-025-00774-2 Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act (Therapeutic Innovation & Regulatory Science) https://link.springer.com/article/10.1007/s43441-024-00706-6 Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications (American Journal of Managed Care) https://www.ajmc.com/view/unintended-consequences-of-the-inflation-reduction-act-clinical-development-toward-subsequent-indications The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs (Value in Health) https://www.valueinhealthjournal.com/article/S1098-3015(25)02527-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301525025276%3Fshowall%3Dtrue Follow John O’Brien on LinkedIn https://www.linkedin.com/in/drjmob/

Episode metadata supplied by the publisher feed · Published Jan 8, 2026

Embed this episode

Ready to play

The National Pharmaceutical Council President and CEO & Former Trump Drug Pricing Advisor, John O’Brien, PharmD, MPH

0:00 37:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Perspectives by the Leerink Center for Pharmacoeconomics?

This episode is 37 minutes long.

When was this Perspectives by the Leerink Center for Pharmacoeconomics episode published?

This episode was published on January 8, 2026.

Can I download this Perspectives by the Leerink Center for Pharmacoeconomics episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!